Beyond Drug Access: Building End-to-End Readiness for Phase 2 of Canada’s Rare Disease Drug Strategy As Canada moves toward Phase 2 of the Rare Disease Drug Strategy, what can we learn from Phase 1, and what needs to be strengthened? This webinar will explore end-to-end readiness through Canadian experiences with hemophilia, thalassemia and sickle cell […]
